Case Study | February 26, 2021
Alternative business models like resale, renting, and reuse platforms, including thredUP, Poshmark, Depop, and The RealReal, have quickly gained popularity and market share in the apparel industry. Resale and reuse business models are increasingly displacing apparel sales by profiting off brand‑name... Not part of subscription
News Commentary | March 19, 2021
The Guardian published a very thoroughly researched article today that shows, with actual quotes and a timeline, how the oil industry has been aware of the detrimental health effects caused by the large‑scale use of its products since the 1960s. This opens the door to litigation similar to what the ... Not part of subscription
News Commentary | January 17, 2022
Kebotix received a Small Business Innovation Research grant from the U.S. Environmental Protection Agency to develop safer alternative diarylide pigments that otherwise may release toxic byproducts at high temperatures. However, the core capability of the company's platform — the closed‑loop ... Not part of subscription
by Xiao Zhong
Zymergen went public on Earth Day this year and promised to generate sales of its first product, Hyaline, in H2 2021. Now it has pushed the target to 2022, and apparently, the public market has not responded well. As discussed in the key issue section of Genomatica's profile, Zymergen is essentially a new materials company based on its platform, and it not only has to develop and productize a material but also needs to develop the market for it. While one can't rule out the possibility of Zymergen creating hype around Hyaline to attract public investors, these kinds of delays should be expected, as materials development is, in essence, hard. Yet, building your own product is still the high-risk, high-reward approach.
For the original news article, click here .